SIMR Announces Postive Results for SR419 in Dose Escalation
On October 15, 2021, Shanghai SIMR Biotechnology Co., Ltd. (hereinafter “SIMR” or “Company”) announced that the single dose escalation study for SR419 has been successfully completed. This Phase I bri...